Latest News and Press Releases

RALEIGH, N.C., May 14, 2009 (GLOBE NEWSWIRE) -- Today DARA BioSciences, Inc. (Nasdaq:DARA) announced that the DB959 program has been identified by Cambridge Healthtech Institute ("CHI") for inclusion...

RALEIGH, N.C., May 12, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) today announced positive results from a Phase 2a clinical trial of KRN5500 for treatment of neuropathic pain in...

RALEIGH, N.C., April 30, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced the appointment of Gail F. Lieberman to its Board of Directors. The appointment was effective April 27,...

RALEIGH, N.C., April 10, 2009 (GLOBE NEWSWIRE) -- DARA Biosciences, Inc. (Nasdaq:DARA) ("DARA" or the "Company"), a development-stage pharmaceutical company, announced today that the audit report...

RALEIGH, N.C., March 30, 2009 (GLOBE NEWSWIRE) -- Today DARA BioSciences, Inc. (Nasdaq:DARA) announced that two abstracts have been accepted for presentation at the annual American Diabetes...

RALEIGH, N.C., March 10, 2009 (GLOBE NEWSWIRE) -- DARA Biosciences, Inc. (Nasdaq:DARA), today announced that the United States Food and Drug Administration ("FDA") has cleared the Company's...

Richard A. Franco, Sr. Appointed as Chief Executive Officer and Director DARA Files Investigational New Drug Application ("IND") With the United States Food and Drug Administration...

RALEIGH, N.C., Oct. 21, 2008 (GLOBE NEWSWIRE) -- DARA Biosciences, Inc. (Nasdaq:DARA), a development-stage pharmaceutical company focused on compounds designed to address diabetes, neuropathic pain...

RALEIGH, N.C., Oct. 2, 2008 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a development-stage pharmaceutical company, announced the completion of all toxicology studies necessary for...

RALEIGH, N.C., Aug. 14, 2008 (PRIME NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) reported today that it expects to restate its financial statements for the quarter ended March 31, 2008, to...